Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.

Publication ,  Journal Article
Reid, IR; Lyles, K; Su, G; Brown, JP; Walsh, JP; del Pino-Montes, J; Miller, PD; Fraser, WD; Cafoncelli, S; Bucci-Rechtweg, C; Hosking, DJ
Published in: J Bone Miner Res
September 2011

Two trials have shown that a single 5-mg infusion of zoledronic acid achieves much higher response rates in Paget disease of bone than risedronate. The duration of this effect is unknown. We have conducted an open follow-up of responders from the two trials (152 originally treated with zoledronic acid, 115 with risedronate) out to 6.5 years without further intervention. Endpoints were times to relapse (ie, return of serum total alkaline phosphatase activity to within 20% of the pretreatment value) or loss of response (response = normalization of alkaline phosphatase or 75% or greater reduction in its excess). Bone turnover markers were lower in the zoledronic acid group throughout follow-up, with mean alkaline phosphatase (ALP) remaining within the reference range in these patients, whereas the mean in the risedronate group was above normal from 1 year. Relapse rates were substantially greater in the risedronate group (23 of 115, 20%) than in those treated with zoledronic acid (1 of 152, 0.7%, p < .001), and loss of response occurred in 19 (12.5%) zoledronic acid patients compared with 71 (62%) risedronate patients (p < .0001). Risk ratios for relapse and loss of response in zoledronic acid patients were 0.02 [95% confidence interval (CI) 0.00-0.18] and 0.12 (95% CI 0.07-0.19), respectively. Changes from baseline in quality of life, assessed using SF-36 scores, were more positive in the zoledronic acid group across the follow-up period (p = .01). Bone markers at 6 months were predictive of response duration. These data demonstrate an unprecedented duration of remission of Paget disease following treatment with zoledronic acid, accompanied by an improved quality of life.

Duke Scholars

Published In

J Bone Miner Res

DOI

EISSN

1523-4681

Publication Date

September 2011

Volume

26

Issue

9

Start / End Page

2261 / 2270

Location

England

Related Subject Headings

  • Zoledronic Acid
  • Treatment Outcome
  • Remission Induction
  • Recurrence
  • Randomized Controlled Trials as Topic
  • Radionuclide Imaging
  • Quality of Life
  • Osteitis Deformans
  • Kaplan-Meier Estimate
  • Infusions, Intravenous
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reid, I. R., Lyles, K., Su, G., Brown, J. P., Walsh, J. P., del Pino-Montes, J., … Hosking, D. J. (2011). A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res, 26(9), 2261–2270. https://doi.org/10.1002/jbmr.438
Reid, Ian R., Kenneth Lyles, Guoqin Su, Jacques P. Brown, John P. Walsh, Javier del Pino-Montes, Paul D. Miller, et al. “A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.J Bone Miner Res 26, no. 9 (September 2011): 2261–70. https://doi.org/10.1002/jbmr.438.
Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res. 2011 Sep;26(9):2261–70.
Reid, Ian R., et al. “A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.J Bone Miner Res, vol. 26, no. 9, Sept. 2011, pp. 2261–70. Pubmed, doi:10.1002/jbmr.438.
Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, Miller PD, Fraser WD, Cafoncelli S, Bucci-Rechtweg C, Hosking DJ. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res. 2011 Sep;26(9):2261–2270.
Journal cover image

Published In

J Bone Miner Res

DOI

EISSN

1523-4681

Publication Date

September 2011

Volume

26

Issue

9

Start / End Page

2261 / 2270

Location

England

Related Subject Headings

  • Zoledronic Acid
  • Treatment Outcome
  • Remission Induction
  • Recurrence
  • Randomized Controlled Trials as Topic
  • Radionuclide Imaging
  • Quality of Life
  • Osteitis Deformans
  • Kaplan-Meier Estimate
  • Infusions, Intravenous